Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity
Juan R. Cubillos-Ruiz, … , Ross Kedl, Jose R. Conejo-Garcia
Juan R. Cubillos-Ruiz, … , Ross Kedl, Jose R. Conejo-Garcia
Published July 13, 2009
Citation Information: J Clin Invest. 2009;119(8):2231-2244. https://doi.org/10.1172/JCI37716.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 7

Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity

  • Text
  • PDF
Abstract

The success of clinically relevant immunotherapies requires reversing tumor-induced immunosuppression. Here we demonstrated that linear polyethylenimine-based (PEI-based) nanoparticles encapsulating siRNA were preferentially and avidly engulfed by regulatory DCs expressing CD11c and programmed cell death 1–ligand 1 (PD-L1) at ovarian cancer locations in mice. PEI-siRNA uptake transformed these DCs from immunosuppressive cells to efficient antigen-presenting cells that activated tumor-reactive lymphocytes and exerted direct tumoricidal activity, both in vivo and in situ. PEI triggered robust and selective TLR5 activation in vitro and elicited the production of hallmark TLR5-inducible cytokines in WT mice, but not in Tlr5–/– littermates. Thus, PEI is a TLR5 agonist that, to our knowledge, was not previously recognized. In addition, PEI-complexed nontargeting siRNA oligonucleotides stimulated TLR3 and TLR7. The nonspecific activation of multiple TLRs (specifically, TLR5 and TLR7) reversed the tolerogenic phenotype of human and mouse ovarian tumor–associated DCs. In ovarian carcinoma–bearing mice, this induced T cell–mediated tumor regression and prolonged survival in a manner dependent upon myeloid differentiation primary response gene 88 (MyD88; i.e., independent of TLR3). Furthermore, gene-specific siRNA-PEI nanocomplexes that silenced immunosuppressive molecules on mouse tumor-associated DCs elicited discernibly superior antitumor immunity and enhanced therapeutic effects compared with nontargeting siRNA-PEI nanocomplexes. Our results demonstrate that the intrinsic TLR5 and TLR7 stimulation of siRNA-PEI nanoparticles synergizes with the gene-specific silencing activity of siRNA to transform tumor-infiltrating regulatory DCs into DCs capable of promoting therapeutic antitumor immunity.

Authors

Juan R. Cubillos-Ruiz, Xavier Engle, Uciane K. Scarlett, Diana Martinez, Amorette Barber, Raul Elgueta, Li Wang, Yolanda Nesbeth, Yvon Durant, Andrew T. Gewirtz, Charles L. Sentman, Ross Kedl, Jose R. Conejo-Garcia

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Total
Citations: 2 7 3 3 5 8 6 4 8 16 7 11 16 11 6 6 4 123
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2013 (16)

Title and authors Publication Year
Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity
JS Dolina, SS Sung, TI Novobrantseva, TM Nguyen, YS Hahn
Molecular Therapy — Nucleic Acids 2013
Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin
H Wei, L Zhao, W Li, K Fan, W Qian, S Hou, H Wang, M Dai, I Hellstrom, KE Hellstrom, Y Guo
PloS one 2013
Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Z Guo, D Cheng, Z Xia, M Luan, L Wu, G Wang, S Zhang
Journal of Translational Medicine 2013
Pathological Mobilization and Activities of Dendritic Cells in Tumor-Bearing Hosts: Challenges and Opportunities for Immunotherapy of Cancer
AJ Tesone, N Svoronos, MJ Allegrezza, JR Conejo-Garcia
Frontiers in immunology 2013
The Yin and Yang of Toll-like receptors in cancer
JP Pradere, DH Dapito, RF Schwabe
Oncogene 2013
New aspects of gene-silencing for the treatment of cardiovascular diseases
O Koenig, T Walker, N Perle, A Zech, B Neumann, C Schlensak, HP Wendel, A Nolte
Pharmaceuticals (Basel, Switzerland) 2013
Delivery of gene silencing agents for breast cancer therapy
H Shen, V Mittal, M Ferrari, J Chang
Breast Cancer Research 2013
Cytokines as biomarkers of nanoparticle immunotoxicity
M Elsabahy, KL Wooley
Chemical Society Reviews 2013
IL12B expression is sustained by a heterogenous population of myeloid lineages during tuberculosis
AE Reeme, HE Miller, RT Robinson
Tuberculosis 2013
Surface charges and shell crosslinks each play significant roles in mediating degradation, biofouling, cytotoxicity and immunotoxicity for polyphosphoester-based nanoparticles
M Elsabahy, S Zhang, F Zhang, ZJ Deng, YH Lim, H Wang, P Parsamian, PT Hammond, KL Wooley
Scientific Reports 2013
Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy
AY Lin, JP Almeida, A Bear, N Liu, L Luo, AE Foster, RA Drezek
PloS one 2013
Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy
S Toraya-Brown, MR Sheen, JR Baird, S Barry, E Demidenko, MJ Turk, PJ Hoopes, JR Conejo-Garcia, S Fiering
Integrative biology : quantitative biosciences from nano to macro 2013
Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment
JR Baird, BA Fox, KL Sanders, PH Lizotte, JR Cubillos-Ruiz, UK Scarlett, MR Rutkowski, JR Conejo-Garcia, S Fiering, DJ Bzik
Cancer research 2013
Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines
BA Fox, KL Sanders, S Chen, DJ Bzik
Trends in Parasitology 2013
Human TLR8 is activated upon recognition of Borrelia burgdorferi RNA in the phagosome of human monocytes
JL Cervantes, CJ la Vake, B Weinerman, S Luu, C O'Connell, PH Verardi, JC Salazar
Journal of leukocyte biology 2013
Toxicity profiling of several common RNAi-based nanomedicines: a comparative study
D Landesman-Milo, D Peer
Drug Delivery and Translational Research 2013

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 1 X users
Referenced in 4 patents
154 readers on Mendeley
See more details